Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -7 of 7
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
GEM012
NCT00407303
First Published:
8/20/2007
2.
Phase I/II Study of Obatoclax Mesylate and Topotecan Hydrochloride in Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI
MSKCC-07082
07-082, 7937, NCT00521144
Last Modified:
8/20/2008
 
First Published:
9/27/2007
3.
Phase I/II Study of Obatoclax Mesylate and Bortezomib in Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
Over 18
NCI
CCC-PHI-58
PHI-58, 7943, NCT00538187
4.
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
GEM017
NCT00682981
Last Modified:
9/16/2008
 
First Published:
7/18/2008
5.
Phase I/II Study of Obatoclax Mesylate and Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
NCI
MAYO-MC068A
MC068A, 7952, NCT00719901
6.
Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
70 and over
Pharmaceutical / Industry
GEM016
NCT00684918
Last Modified:
6/4/2008
 
First Published:
2/6/2008
7.
Phase I Study of Obatoclax Mesylate, Fludarabine Phosphate, and Rituximab in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
DFCI-07100
07-100, 7945, NCT00612612
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute